Aurinia Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Aurinia Pharmaceuticals

02/11/2023 13:31

* Aurinia Pharmaceuticals Inc  AUPH.OQ  reported a quarterly
adjusted loss of 9 cents​​ per share for the quarter ended in
September, lower than the same quarter last year, when the
company reported EPS of -6 cents.  The mean expectation of
seven analysts for the quarter was for a loss of 17 cents per
share. Wall Street expected results to range from -19 cents
to -13 cents per share.
    * Revenue fell 2.3% to $54.52 million from a year ago;
analysts
expected $38.50 million. 
    * Aurinia Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 9 cents​.
    * The company reported a quarterly loss of $13.45 million.
    * Aurinia Pharmaceuticals Inc shares had fallen by 8.2% this
quarter and gained 65.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Aurinia
Pharmaceuticals Inc is $15.00 

This summary was machine generated from LSEG data November 2 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.17          -0.09          Beat
 Jun. 30 2023      -0.18          -0.08          Beat
 Mar. 31 2023      -0.22          -0.18          Beat
 Dec. 31 2022      -0.27          -0.18          Beat